

UTILITY PATENT APPLICATION TRANSMITTAL TRANSMITTAL TRANSMITTAL

Signature:

Name:

0010-1066-0 Attorney Docket No.

First Inventor or Application Identifier Vitality A. LIVSHITS, et al.

Title METHOD FOR PRODUCING L-AMINO ACID

Date:

Registration No.:



	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ADDI	RES	Assistant Commissioner for Patents S TO: Box Patent Application Washington, DC 20231	
1.	Fee Transmittal Form (e.g. PTO/SB/17) (Submit an onginal and a duplicate for fee processing)			ACCOMPANYING APPLICATION PARTS	
	(g)	6.		Assignment Papers (cover sheet & document(s))	
2.	■ Specification Total Pages 58	7.		37 C.F.R. §3.73(b) Statement Power of Attorney	
		8.		English Translation Document (if applicable)	
3.	□ Drawing(s) (35 U.S.C. 113) Total Sheets	9.		Information Disclosure Copies of IDS Statement (IDS)/PTO-1449	
		10.		Preliminary Amendment	
4.		11.		White Advance Serial No. Postcard	
a land	a. ■ Newly executed (original) b. □ Copy from a prior application (37 C.F.R. §1.63(d)) (for continuation/divisional with box 15 completed)	12.		Small Entity Statement(s) Statement filed in prior application. Status still proper and desired.	
1 2	i. 👝	13.	•	Certified Copy of Priority Document(s)(2)	
Hard Shall Share the state of the shall sh	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.25(8). Incorporation By Reference (usable if hox 48 is checked) the entire disclosure of the prior application, from which a copy of the other dependence is supplied under Box 48, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference herein.	14.	•	Notice of Priority, Receipt of an Original Deposit of Microorganisms for the Children of Microorganisms for the Children of Microorganisms for the Children of WKPM B-7707, VKPM B-7708, VKPM B-7716, VKPM B-7715, VKPM B-7715, VKPM B-7715, VKPM B-7715, VKPM B-7715, VKPM B-7718, VKPM B-7712, VKPM B-7722, VKPM B-7730, VKPM B-7731, VKPM B-7732, VKPM B-7732, VKPM B-7731, VKPM B-7732, VKPM B-7735, VKPM B-7734)	
15.	If a CONTINUING APPLICATION, check appropriate box, and suppl	ly the r	equis	ite information below:	
	□ Continuation □ Divisional □ Continuation-i	in-pai	t (C	IP) of prior application no.:	
	Prior application information: Examiner:			Group Art Unit:	
16.	Amend the specification by inserting before the first line the se	nten	æ:		
	□ This application is a □ Continuation □ Division □ Continuation-in-part (CIP) of application Serial No. Filed on				
0	☐ This application claims priority of provisional application Serial No. Filed				
17. CORRESPONDENCE ADDRESS					
	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 413-3000 FACSIMILE: (703) 413-2220				
-			_		
	Name: Norman F. Oblon		\	Registration No.: 24,618	

MARVIN J. SPIVAK REGISTRATION NUMBER 24,913

METHOD FOR PRODUCING L-AMINO ACID

Technical Field ~

The present invention relates to a method for producing an amino acid. In particular, the present invention relates to an L-amino acid-producing bacterium belonging to the genus Escherichia and a method for producing L-amino acids, more specifically, L-glutamic acid, L-lysine, L-threonine, L-alanine, L-histidine, L-proline, L-arginine, L-valine, and L-isoleucine, using the bacterium.

Background Art

For production of an L-amino acid by fermentation, a strain isolated from the natural world or an artificial mutant of the strain has been used to improve productivity. For example, in the case of L-lysine, many artificial mutants producing L-lysine are known, and most of them are mutants resistant to S-2-aminoethylcysteine (AEC) and belong to the genus Brevibacterium, Corynebacterium, Bacillus or Escherichia. Also, there have been proposed various technics for increasing amino acid production such as use of a transformant obtained by using a recombinant DNA (U.S. Patent No. 4,278,765).

The technics are mostly based on enhancement of an activity of an enzyme involved in an amino acid biosynthetic pathway, conversion of the enzyme to that desensitized in

25

20

15

inhibition and the like (As to bacterium belonging the genus Escherichia, see Japanese Patent Application Laid-Open No. 56-18596 (1981) and International Publication No. WO 95/16042).

On the other hand, as an example of improvement of amino acid productivity by enhancing an amino acid excretion protein, a bacterium belonging to the genus Corynebacterium in which an L-lysine excretion gene, lysE is enhanced is known. However, as to bacteria belonging to the genus Escherichia, it is unknown even whether an L-amino acid excretion protein is present or not. Therefore, it is unknown whether enhancement of the L-amino acid excretion protein is effective in L-amino acid production using a bacterium belonging to the genus Escherichia or not.

Although the entire nucleotide sequence of *E. coli* strain K-12 belonging to the genus *Escherichia* has been already determined (Science, 277, 1453-1474(1997)), there are a large number of proteins of which functions are unknown.

20

25

5

10

15

Disclosure of the Invention

An object of the present invention is to obtain a protein participating in excretion of an L-amino acid, thereby providing a strain improved in L-amino acid productivity and an improved method for producing an L-amino acid by fermentation.

The inventors have conducted screening for the protein

10

15

20

25

participating in excretion of an L-amino acid. As a result, the present inventors have found that a yield of an L-amino acid based on consumed sugar is increased when a particular gene is enhanced. On the basis of the finding, the present invention has been completed.

Thus, the present invention provides a bacterium belonging to the genus *Escherichia* and having an ability to produce an L-amino acid, wherein the ability to produce the L-amino acid is increased by increasing an expression amount of at least one protein selected from the group consisting of the following proteins of (A) to (H) (hereinafter also referred to as "the bacterium of the present invention"):

- $\mbox{(A)} \quad \mbox{a protein having an amino acid sequence shown in SEQ ID NO: 10 in Sequence Listing;}$
- (B) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 10 in Sequence Listing, and which has an activity of increasing the ability to produce the L-amino acid of the bacterium having the protein;
- (C) a protein having an amino acid sequence shown in SEQ ID NO: 12 in Sequence Listing;
- (D) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 12 in Sequence Listing, and which has an activity of increasing the ability to produce the

10

15

20

25

L-amino acid of the bacterium having the protein;

- (E) a protein having an amino acid sequence shown in SEQ ID NO: 14 in Sequence Listing;
- (F) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 14 in Sequence Listing, and which has an activity of increasing the ability to produce the L-amino acid of the bacterium having the protein;
- (G) a protein having an amino acid sequence shown in SEQ ID NO: 16 in Sequence Listing; or
- (H) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 16 in Sequence Listing, and which has an activity of increasing the ability to produce the L-amino acid of the bacterium having the protein.

The bacterium of the present invention preferably an L-lysine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (A) to (D), (G) and (H) is increased; an L-glutamic acid-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (A) to (H) is increased; an L-alanine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (C) and (D) is increased; an L-valine-

10

15

20

25

producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (C) and (D) is increased; an L-histidine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (C) to (F) is increased; an L-proline-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (A) to (F) is increased; an L-threonine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (E) and (F) is increased; an L-arginine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (G) and (H) is increased; or an L-isoleucine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.

Preferably, in the bacterium of the present invention, a copy number of a DNA coding for said protein in a cell is increased. The DNA is preferably carried on a multicopy vector in the cell or on a transposon in the cell.

The present invention also provides a method for producing an L-amino acid, comprising the steps of:

cultivating the bacterium of the present invention in a culture medium, to produce and accumulate the L-amino acid in the medium, and

recovering the L-amino acid from the medium

10

15

20

25

(hereinafter also referred to as "the bacterium of the present invention").

The method of the present invention preferably an L-lysine production method using an L-lysine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (A) to (D), (G) and (H) is increased; an L-glutamic acid production method using an L-glutamic acid-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (A) to (H) is increased; an L-alanine production method using an L-alanine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (C) and (D) is increased; an L-valine production method using an L-valine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of the proteins (C) and (D) is increased; an L-histidine production method using an L-histidine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (C) to (F) is increased; an L-proline production method using an L-proline-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (A) to (F) is increased; an L-threonine production method using an L-threonine-producing bacterium in which an expression amount of at least one protein selected from the

15

20

25

group consisting of said proteins (E) and (F) is increased; an L-arginine production method using an L-arginine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (G) and (H) is increased; or an L-isoleucine production method using an L-isoleucine-producing bacterium in which an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.

Preferably, in the method of the present invention, a copy number of a DNA coding for said protein in a cell of the bacterium is increased. The DNA is preferably carried on a multicopy vector in the cell, or on a transposon in the cell.

According to the present invention, an ability to produce an L-amino acid of a bacterium belonging to the genus Escherichia can be increased. Also, a method for producing an L-amino acid can be improved in a production rate of an L-amino acid.

The present invention will be explained in detail below. Hereinafter, an amino acid is of L-configuration unless otherwise noted

<1> Bacterium of the present invention

The bacterium of the present invention is a bacterium belonging to the genus *Escherichia* and having an ability to produce an amino acid, in which the ability to produce the amino acid is increased by increasing an expression amount

15

20

25

of a protein which has an activity of increasing the ability to produce the amino acid of the bacterium, or an activity of increasing resistance to an amino acid or amino acid analogue. Hereinafter, the protein is referred to as "amino acid excretion protein" for the sake of convenience. However, the term does not mean that function of the protein

However, the term does not mean that function of the protein is limited to amino acid excretion.

Examples of the amino acid excretion protein include a protein having an amino acid sequence shown in SEQ ID NO: 10, a protein having an amino acid sequence shown in SEQ ID NO: 12, a protein having an amino acid sequence shown in SEQ ID NO: 14 and a protein having an amino acid sequence shown in SEQ ID NO: 16.

The amino acid excretion protein may have selectivity to amino acid. An amino acid excretion protein appropriate for each amino acid can be determined by allowing the amino acid excretion protein to be expressed in a bacterium belonging to the genus *Escherichia* and having an ability to produce the amino acid, and measuring an increase of a yield of the amino acid or measuring an increase of a minimum inhibition concentration (MIC) of an amino acid or amino acid analogue.

For example, in the case of lysine, a protein having an amino acid sequence shown in SEQ ID NO: 10, 12 or 16 is effective; in the case of glutamic acid, a protein having an amino acid sequence shown in SEQ ID NO: 10, 12, 14 or 16 is effective; in the case of alanine, a protein having an

amino acid sequence shown in SEQ ID NO: 12 is effective; in the case of valine, a protein having an amino acid sequence shown in SEQ ID NO: 12 is effective; in the case of histidine, a protein having an amino acid sequence shown in SEQ ID NO: 12 or 14; in the case of proline, a protein having an amino acid sequence shown in SEQ ID NO: 10, 12 or 14 is effective; in the case of threonine, a protein having an amino acid sequence shown in SEQ ID NO: 14 is effective; in the case of arginine, a protein having an amino acid sequence shown in SEQ ID NO: 16 is effective; and in the case of isoleucine, a protein having an amino acid sequence shown in SEQ ID NO: 12 is effective.

The term "an expression amount is increased" used herein usually means that the expression amount is larger than that in a wild strain of *E. coli* such as strain MG1655 or W3110. The terms also means that when a strain is obtained by modification through genetic engineering technics or the like, the expression amount is larger than that prior to the modification. The expression amount of the amino acid excretion protein may be determined directly by the determination of the amino acid excretion protein or indirectly by the determination of MIC of an amino acid or amino acid analogue or of amino acid productivity of a bacterium belonging to the genus *Escherichia* and having the amino acid excretion protein.

The method for increasing the expression amount of the amino acid excretion protein is exemplified by a method for

15

20

25

increasing a copy number of DNA encoding the amino acid excretion protein in a cell of the bacterium.

For increasing the copy number in the cell, a DNA fragment coding for the amino acid excretion protein may be ligated to a vector which functions in a bacterium belonging to the genus Escherichia to produce a recombinant DNA, which is introduced to a host to transform it. The copy number of the gene coding for the amino acid excretion protein (amino acid excretion protein gene) in the cell of the transformant strain increases, thereby increasing the expression amount of the amino acid excretion protein. The vector is preferably a multicopy vector.

The increase of the copy number in the cell can be achieved by allowing plural copies of the amino acid excretion protein gene to exist on chromosomal DNA of the host. The introduction of plural copies of the amino acid excretion protein gene to chromosomal DNA of a bacterium belonging to the genus Escherichia, may be conducted through homologous recombination by using a sequence of which plural copies exist on the chromosomal DNA, as a target. As the sequence of which plural copies exist on the chromosomal DNA, a repetitive DNA and an inverted repeat present in a terminal portion of a transposable element may be used.

Alternatively, as disclosed in Japanese Patent Application Laid-Open No. 2-109985 (1990), the plural copies can be introduced to the chromosomal DNA by making the amino acid excretion protein gene carried on a transposon and allowing

15

20

25

the transposon to be transposed, which is preferred. According to any of the above-mentioned methods, the copy number of the amino acid excretion protein gene in the transformant strain increases, thereby increasing the expression amount of the amino acid excretion protein.

The multicopy vector is exemplified by plasmid vectors such as pBR322, pMW118, pUC19 or the like, and phage vectors such as $\lambda 1059$, $\lambda BF101$, M13mp9 or the like. The transposon is exemplified by Mu, Tn10, Tn5 or the like.

The introduction of a DNA into a bacterium belonging to the genus *Escherichia* can be performed, for example, by a method of D. M. Morrison (Methods in Enzymology 68, 326 (1979)) or a method in which recipient bacterial cells are treated with calcium chloride to increase permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)) and the like.

Besides the above-mentioned gene amplification, the increase of the expression amount of the amino acid excretion protein can be also achieved by replacing an expression regulatory sequence such as a promoter of the amino acid excretion protein gene with stronger one (see Japanese Patent Application Laid-Open No. 1-215280 (1989)). For example, lac promoter, trp promoter, tac promoter, $P_{\rm g}$ promoter and $P_{\rm L}$ promoter of lambda phage, and the like are known as a strong promoter. The replacement with the promoter enhances expression of the amino acid excretion protein, thereby increasing the expression amount of the

10

15

20

25

amino acid excretion protein. The enhancement of the expression regulatory sequence may be combined with the increase of the copy number of the amino acid excretion protein.

In the bacterium of the present invention, expression amounts of plural amino acid excretion proteins may be increased.

The amino acid excretion protein is encoded by genes which are known as yahN gene, yeaS gene, yfiK gene and yggA gene and of which functions are unknown. Therefore, the DNA encoding the amino acid excretion protein can be obtained by synthesizing primers based on the known sequences (for example, the entire nucleotide sequence of chromosome of Escherichia coli strain K-12 has been already determined (Science, 277, 1453-1474(1997))), and conducting amplification by PCR using chromosomal DNA of a bacterium belonging to the genus Escherichia as a template. Also, the object DNA fragment can be selected by hybridization from a chromosomal DNA library of a bacterium belonging to the genus Escherichia by preparing a probe based on the known sequences. Alternatively, the DNA encoding the amino acid excretion protein may be synthesized based on the known sequences. The nucleotide sequence of the DNA encoding the amino acid excretion protein is exemplified by that shown in SEQ ID NO: 9, 11, 13 or 15 in the Sequence Listing.

Methods for preparation of chromosomal DNA, preparation of chromosomal DNA library, hybridization, PCR,

15

20

25

preparation of plasmid DNA, digestion and ligation of DNA, transformation, selection of an oligonucleotide as a primer and the like may be ordinary methods well known to one skilled in the art. These methods are described in Sambrook, J., Fritsch, E. F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989) and the like.

The amino acid excretion protein may comprise substitution, deletion, insertion, addition or inversion of one or several amino acids at one or a plurality of positions, provided that the activity of increasing the ability to produce the amino acid of the bacterium belonging to the genus Escherichia and having the protein is not deteriorated. The term "several" may vary depending on a position in a steric structure of the protein and a kind of an amino acid residue. It is because some amino acids such as isoleucine and valine have high similarity to each other, and a difference between such the amino acids does not largely affect the steric structure of the protein.

The DNA which codes for the substantially same protein as the amino acid excretion protein as described above, may be obtained, for example, by modifying the nucleotide sequence, for example, by means of the site-directed mutagenesis method so that one or more amino acid residues at a specified site involve substitution, deletion, insertion, addition or inversion. The DNA modified as described above may be obtained by the conventionally known

10

15

20

25

mutation treatment. The mutation treatment includes a method for treating a DNA coding for the amino acid excretion protein *in vitro*, for example, with hydroxylamine, and a method for treating a microorganism, for example, a bacterium belonging to the genus *Escherichia*, harboring a DNA coding for the amino acid excretion protein with ultraviolet irradiation or a mutating agent such as N-methyl-N'-nitro-N-nitrosoguanidine (NG) and nitrous acid usually used for the mutation treatment.

The substitution, deletion, insertion, addition or inversion of the one or more amino acid residues includes a naturally-occurring mutation or variation which is resulted from a difference between individual microorganisms having the amino acid excretion protein and a difference between species, strains or the like.

The DNA, which codes for substantially the same protein as the amino acid excretion protein, can be obtained by allowing a DNA having the mutation as described above to be expressed in a cell of an appropriate bacterium belonging to the genus Escherichia, and investigating the increase of amino acid productivity of the cell.

Also, the DNA, which codes for substantially the same protein as the amino acid excretion protein, can be obtained by isolating a DNA which hybridizes with DNA having, for example, a nucleotide sequence shown in SEQ ID NO: 9, 11, 13 or 15 in Sequence Listing under stringent conditions, and which codes for a protein having the activity of increasing

the ability to produce the amino acid of the bacterium belonging to the genus *Escherichia*, from DNAs encoding the amino acid excretion proteins having mutations or cells containing the DNAs. The term "stringent conditions" referred to herein means a condition under which a specific hybrid is formed, and a non-specific hybrid is not formed. It is difficult to clearly express this condition by using any numerical value. However, for example, the stringent conditions include a condition under which DNAs having high homology, for example, DNAs having homology of not less than 70% with each other are hybridized, and DNAs having homology lower than the above with each other are not hybridized, or a condition of a salt concentration corresponding to 60°C, lx SSC, 0.1% SDS, preferably 0.1x SSC, 0.1% SDS which is a washing condition of ordinary Southern hybridization.

Although there may be a gene in which a stop codon is made in the middle, or a gene encoding a protein losing the activity due to mutation of the active center among the genes which hybridize under such the condition, such genes can be easily eliminated by ligating the genes to a commercially available activity-expression vector and determining the activity of increasing the ability to produce the amino acid of the bacterium belonging to the genus *Escherichia* as described above.

The term "DNA coding for a protein" used herein means a DNA of which one of strands codes for the protein when the DNA is double-stranded.

10

15

20

25

By increasing an expression amount of an amino acid excretion protein in an amino acid-producing bacterium belonging to the genus Escherichia as described above, a produced amount of the amino acid can be increased. As the bacterium belonging to the genus Escherichia in which the expression amount of the amino acid excretion protein is to be increased, strains which have abilities to produce desired amino acids (amino acid productivities) are used. Besides, an ability to produce an amino acid may be imparted to a bacterium in which the expression amount of the amino acid excretion protein is increased. Examples of amino acid-producing bacteria belonging to the genus Escherichia include E. coli AJ13199 (FR patent No. 2747689), and those obtainable from known materials (e.g., E. coli W3110 (tyrA)/pCABD2, E. coli VL614, E. coli VL2054, E. coli VL2160, E. coli VL2151, E. coli W3350 argE::Tn10/pKA10 as described in the Examples below).

For reference, the amino acid excretion protein according to the present invention was identified for the first time as described below.

The present inventors have identified rhtB and rhtC as threonine excretion protein genes of a bacterium belonging to the genus Escherichia. The present inventors searched databases based on a hypothesis that amino acid excretion proteins may share a common structure. Namely, BLAST and PSI-BLAST search (Altschul, S.F. et al., Nucleic Acids Res., 25, 3389-3402(1997)) for homology of a protein encoded by

15

20

25

rhtB was performed in GenBank CDS, PDB, SWISS-PROT, Spupdate and PIR. Tblastn search was performed in unfinished microbial genomes. BLITZ search (Sturrock, S.S., and Collins, J.F., Mpsch version 1.3. Biocomputing research unit University of Edinburgh, UK (1993)) was performed in SWALL database. SMART search (Ogiwara, I. et al., Protein Sci., 5, 1991-1999 (1996)) was performed in the databases of translations and SWISS-PROT. From the samples of more than 60 sequences found, YeaS (corresponding to f212 of ACCESSION No. AE000274 in GenBank), YahN (corresponding to f223 of ACCESSION No. AE000140 in GenBank), Yfik (corresponding to o195 of ACCESSION No. AE000344 in GenBank) and YggA (corresponding to f211 of ACCESSION No. AE000375 in GenBank) remained as proteins which may have similar function to RhtB, among those originating from E. coli. Since functions of any of these genes were unknown, the genes were actually obtained, and effects thereof on MIC of amino acids and amino acid analogues and on amino acid production were examined by enhancing activities thereof. As a result, an effect of increasing MIC of some amino acids and analogues was found with respect to YeaS, YfiK, YahN and YggA. Further examination has revealed that proteins encoded by these genes exhibit an effect of increasing an amino acid accumulation, although they may have some amino acid selectivities.

<2> Method of the present invention

5

10

15

20

25

The method of the present invention comprises the steps of cultivating the bacterium of the present invention, in a culture medium, to produce and accumulate the amino acid in the medium, and recovering the amino acid from the medium.

Suitable amino acids include lysine, glutamic acid, alanine, valine, homoserine, proline, and threonine.

In the method of present invention, the cultivation of the bacterium belonging to the genus Escherichia, the collection and purification of amino acid from the liquid medium may be performed in a manner similar to those of the conventional method for producing an amino acid by fermentation using a bacterium. A medium used in cultivation may be either a synthetic medium or a natural medium, so long as the medium includes a carbon and a nitrogen source and minerals and, if necessary, nutrients which the bacterium used requires for growth in appropriate amounts. The carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on assimilatory ability of the used bacterium, alcohol including ethanol and glycerol may be used. As the nitrogen source, ammonia, various ammonium salts such as ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean hydrolyte and digested fermentative microbe are used. As minerals, monopotassium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium carbonate are used.

The cultivation is preferably culture under an aerobic condition such as a shaking culture, and an aeration and stirring culture. The temperature of culture is usually 20 to 40°C, preferably 30 to 38°C. The pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2. The pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 3-day cultivation leads to the accumulation of the target amino acid in the medium.

Recovering the amino acid can be performed by removing solids such as cells from the medium by centrifugation or membrane filtration after cultivation, and then collecting and purifying the target amino acid by ion exchange, concentration and crystalline fraction methods and the like.

15

25

5

10

Best Mode for Carrying Out the Invention The present invention will be more concretely explained below with reference to Examples.

Example 1. Preparation of the DNA fragments which code for amino acid excretion proteins.

The entire nucleotide sequence of chromosome of *E. coli* strain K-12 has been determined (Science, 277, 1453-1474, 1997). Based on the reported nucleotide sequence, primers were synthesized and the genes *yahN*, *yfiK*, *yeaS* and *yggA* were amplified by PCR.

15

20

25

 Chromosomal DNA of the E. coli strain MG1655 was used as a template.

The chromosomal DNA was preapared by an ordinary method (Sambrook, J., Fritsch E. F. and Maniatis T. (1989) Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.). In the PCR reaction, a standard condition described in "PCR protocols. Current methods and applications". (White, B.A., ed. Humana Press, Totowa, New Jersey, 1993) was used. The obtained PCR products were purified by an ordinary method and digested with restriction enzymes as described below.

The yahN gene was amplified by using the primers No.1 and No. 2.

Primer No.1: gtgtggaaccgacgccggat (a sequence complementary to a sequence of from 1885 base to 1904 base in a nucleotide sequence registered under ACCESSION No. AE000140 in GenBank; SEQ ID NO: 17), and

Primer No.2: tgttgtatggtacggggttcgag (a sequence of from 223 base to 245 base in the same; SEQ ID NO: 18).

The obtained PCR product after purification was digested with restriction enzymes PstI and StuI and ligated to vector pUC21 (Vieira, Messing, Gene, 100, 189-194, 1991) digested with the enzymes PstI and EcoRV by using a ligation kit. Then, transformation of competent cells of E. coli TG1 (Sambrook, J., Fritsch E. F. and Maniatis T. (1989) Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory

15

20

Press, Cold Spring Harbor, N. Y.) with the product was conducted and the cells were spread on L medium (10 g/l Bacto trypton, 5 g/l Yeast extract, 5 g/l NaCl, 15 g/l agar, pH 7.0) containing 10 mg/ml IPTG (isopropyl-β-p-

thiogalactopyranoside) and 40 mg/ml X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) and 100 mg/ml ampicillin, and cultured overnight. Appeared white colonies were picked up and subjected to single colony isolation to obtain transformants. Plasmid was prepared from the transformants using an alkali extraction method and designated as pYAHN.

The yeaS gene was amplified by using the primers No.3 and No. 4.

Primer No.3: ctttgccaatcccgtctccc (a sequence complementary to a sequence of from 7683 base to 7702 base in a nucleotide sequence registered under ACCESSION No AE000274 in GenBank; SEQ ID NO: 19);

Primer No.4: gccccatgcataacggaaag (a sequence of from 5542 base to 5561 base in the same; SEQ ID NO: 19).

The obtained PCR product after purification was digested with a restriction enzyme AvaI and ligated to vector pUC19. After transformation of E. coli TG1 as above, the plasmid designated as pYEAS was obtained.

The yfiK gene was amplified by using the primers No.5 and No.6.

25 Primer No.5: gaagatcttgtaggccggataaggcg (a sequence of from 4155 base to 4177 base in a nucleotide sequence

15

20

25

registered under ACCESSION No AE000344 in GenBank, with a restriction enzyme BglII site added at the 5'-end thereof; SEQ ID NO: 21)

Primer No.6: tggttttaccaattggccgc (a sequence complementary to a sequence of from 6307 base to 6326 base in the same: SEO ID NO: 22).

The obtained PCR product after purification was digested with restriction enzymes BglII and MunI and ligated to vector pUC21 digested with restriction enzymes BglII and EcoRI. After transformation of E. coli TG1 as above, the plasmid designated pYFIK was obtained.

The yggA gene was amplified by using the primers No.7 and No.8.

Primer No.7: acttctcccgcgagccagttc (a sequence complementary to a sequence of from 9606 base to 9626 base in a nucleotide sequence registered under ACCESSION No AE000375 in GenBank; SEQ ID No: 23).

Primer No.8: ggcaagcttagcgcctctgtt (a sequence of from 8478 base to 8498 base in the same; SEQ ID No: 24).

The obtained PCR product after purification was digested with restriction enzymes *Hind*III and *Cla*I and ligated to vector pOK12 (Vieira, Messing, Gene, 100, 189-194, 1991) digested with the same restriction enzymes. After transformation of *E. coli* TG1 as above, the plasmid designated pYGGA was obtained.

15

20

(2). Chromosomal DNA of the $\it E.~coli$ strain W3110 was used as a template.

The yahN gene was amplified by using the primers No.9 (SEQ ID NO.1) and No. 10 (SEQ ID NO.2)

The yeas gene was amplified by using the primers No.11 (SEQ ID NO 3) and No.12 (SEQ ID NO 4)

The yfiK gene was amplified by using the primers No.13 (SEQ ID NO 5) and No.14 (SEO ID NO 6).

The yggA gene was amplified by using the primers No.15 (SEQ ID NO 7) and No.16 (SEQ ID NO 8)

The obtained PCR product was purified, digested with restriction enzymes SacI and XbaI (EcoRI and PstI for yggA), and ligated to plasmid pMW118 (Nippon Gene). The plasmid into which a DNA fragment of which sequence was identical to the reported sequence was inserted was designated as follows:

One carrying yahn: pMwl18::yahn
One carrying yeaS: pMwl18::yeaS
One carrying yfik: pMwl18::yfik
One carrying ygqA: pMwl18::yqqA

Example 2. Effect of the yahn, yeaS, yfiK, and yggA DNA fragments amplification on the E. coli TG1 resistance to some amino acids and amino acid analogues.

25 The homology of the yeaS, yfiK, yahN and yggA gene products with the lysine transporter, LysE, of

15

20

25

glutamicum (Vrljic Corvnebacterium et al., Microbiol., 22, 815-826, 1996) and RhtB protein involved in homoserine excretion, indicates the analogues function for these proteins. It is well known that the increased expression of the genes involved in antibiotic and heavy metal efflux increases the level of resistance to the drugs (Nikaido, H. J. Bacteriology, 178, 5853-5859, 1996). Therefore, the effect of the pYEAS, pYAHN, pYFIK, and pYGGA plasmids on susceptibility of the strain TG1 to some amino acids and amino acid analogues was tested. Overnight cultures of the E. coli strains TG1/pYEAS, TG1/pYAHN, TG1/pYFIK, TG1/pYGGA and of the control strains TG1/pUC21, TG1/pUC19 and TG1/pOK12 grown in M9 minimal medium with an appropriate antibiotic on a rotary shaker (10° cfu/ml) were diluted 1:100 in M9 minimal medium and grown for 5 h in the same medium. Then the log phase cultures thus obtained were diluted and about 104 alive cells were applied to well-dried test plates with M9 agar containing doubling increments of amino acids or analogues. Thus the minimum inhibition concentration (MIC) of these compounds were examined.

The results are shown in Table 1. It follows from the Table 1 that multiple copies of yfiK gene conferred increased resistance to proline, homoserine, histidine, threonine, glutamate, lysine, α -amino- β -hydroxyvaleric-acid (AHVA), S-(2-aminoethyl)-L-cysteine (AEC) and α -aminobutyric acid; multiple copies of yahN gene conferred increased resistance to proline, multiple copies of yeaS gene conferred increased

resistance to threonine, homoserine, lysine, glutamate, histidine, proline and α -aminobutyric acid; multiple copies of yggA gene conferred increased resistance to S-(2-aminoethyl)-L-cysteine (AEC), lysine, and arginine. These results indicate that except for YahN, every of the presumed transporters have specificity to several substrates (amino acids and amino acid analogues), or may show non-specific effects as a result of amplification.

10

Table 1

Substrate	MIC (μg/ml) for E. coli TG1,						
		harboring the plasmid					
	pUC21	pYFIK	pYAHN	pYEAS	pYGGA		
L-homoserine	500	1000	500	1000	500		
L-threonine	30000	40000	30000	50000	30000		
L-lysine	5000	7500	5000	7500	15000		
L-glutamate (Na salt)	5000	10000	5000	20000	5000		
L-histidine	5000	10000	5000	30000	5000		
L-valine	0.5	0.5	0.5	0.5	0.5		
L-proline	1000	5000	2000	2000	1000		
L-arginine	10000	10000	10000	10000	20000		
AHVA	100	200	100	100	100		
AEC	5	10	5	5	200		
α -aminobutyric acid	2500	5000	2500	>10000	2500		
4-aza-DL-leucine	100	100	100	100	100		

Example 3. Effect of yeas, yahn, and yfik DNA fragments amplification on glutamic acid production.

The $\it E.~coli$ strain AJ13199 (FR patent No. 2747689) was transformed with the vector pUC21 and each of the plasmids

15

pYAHN, pYEAS and pYFIK. Thus the strains AJ13199/pUC21 (VKPM B-7728), AJ13199/pYAHN (VKPM B-7729), AJ13199/pYEAS (VKPM B-7731), and AJ13199/pYFIK (VKPM B-7730) were obtained.

These strains were each cultivated at 37°C for 18 hours in a nutrient broth with 100 mg/l ampicillin, and 0.3 ml of the obtained culture was inoculated into 3 ml of a fermentation medium containing 100 mg/l ampicillin, in a 20 x 200 mm test tube, and cultivated at 37°C for 48 hours with a rotary shaker. After the cultivation, an accumulated amount of glutamic acid in the medium was determined by known method.

The composition of the fermentation medium (g/1):

15	Glucose	80
	$(NH_4)_2SO_4$	22
	K_2HPO_4	2
	NaCl	0.8
	${ m MgSO_4\cdot 7H_2O}$	0.8
20	$FeSO_4 \cdot 7H_2O$	0.02
	$MnSO_4 \cdot 5H_2O$	0.02
	Thiamine HCl	0.0002
	Yeast extract	1.0
	CaCO ₃	30.0 (dry-heat-sterilized at 180°C
25		for 2 h)

(Glucose and K2HPO4 separately sterilized)

The results are shown in Table 2. As shown in Table 2, the strains AJ13199/pYAHN, AJ13199/pYEAS, and AJ13199/pYFIK accumulated glutamic acid in a larger amount than the strain AJ13199/pUC21 in which an expression amount of amino acid excretion proteins was not enhanced.

Table 2.

Strain	Glutamic acid, g/l
AJ13199/pUC21	21.9
AJ13199/pYAHN	27.9
AJ13199/pYEAS	29.7
AJ13199/pYFIK	28.4

Example 4. Effect of yeaS, yahN, and yfiK DNA fragments amplification on lysine production.

(1). As the lysine-producing bacterium belonging to the genus Escherichia, E. coli strain W3110 (TyrA) described in European Patent Publication No. 488424 to which plasmid pCABD2 was introduced, described in International Publication No. WO 95/16042) was used. Specifically, plasmid pCABD2, and each of the plasmid pMW118::yahN, pMW118::yeaS, pMW118::yfiK and pMW118 were introduced to E. coli strain W3110 (TyrA) to obtain the following strains: W3110 (tyrA)/pCABD2+pMW118::yahN

W3110 (tyrA)/pCABD2+pMW118::yeaS W3110 (tyrA)/pCABD2+pMW118::yfik W3110 (tyrA)/pCABD2+pMW118.

10

15

20

Lysine productivity of these strains was estimated by culture. The composition of the used medium was as follows (9/1):

Glucose	40.0
MgSO ₄ ·7H ₂ O	1.0
$(NH_4)_2SO_4$	16.0
K_2HPO_4	1.0
FeSO ₄ ·7H ₂ O	0.01
MnSO ₄ ·7H ₂ O	0.01
Yeast extract (Difco)	2.0
Tyrosine	0.1

Adjusted to pH 7.0 and autoclaved at 115° C for 10 minutes. (Glucose and MgSO, $^{\circ}7H_{2}O$ separately sterilized)

Pharmacopeial CaCO $_3$ 25 g/l (dry-heat-sterilized at 180°C for 2 h)

As antibiotics, 20 mg/l of streptomycin and 50 mg/l of ampicillin were added depending on a kind of a plasmid. Cultivation was conducted at 37° C for 30 hours with agitation at 115 rpm. The results are shown in Table 3.

Table 3

Strain	Lysine,	Yield,
	g/1	(%)
W3110(tyrA)	0.08	0.2
W3110(tyrA)/pCABD2 + pMW118	12.2	30.5
W3110(tyrA)/pCABD2 + pMW118::yahN	13.8	34.5
W3110(tyrA)/pCABD2 + pMW118::yeaS	12.7	31.8
W3110(tyrA)/pCABD2 + pMW118::yfiK	12.2	30.5

20

5

10

15

10

15

20

25

The result in Table 3 shows that the produced amount and the yield based on consumed sugar of lysine is increased by enhancement of YahN and YeaS.

(2). As the lysine-producing bacterium belonging to the genus *Escherichia*, *E. coli* strain VL614 was used. This strain is a derivative of the known *E. coli* strain VL613 (SU Patent No. 1354458). In turn, the strain VL613 was obtained from the known strain Gifl02 (Theze, J. and Saint Girons. J.Bacteriol., 118, 990-998, 1974) in the three steps:

At the first step the mutants resistant to 2 mg/ml S-(2-aminoethyl)-L-cysteine were selected and among them the strain VL611 was found capable to produce L-lysine.

At the second step the genes involved in sucrose utilization and located on the transposon Tn2555 (Doroshenko et al., Mol. Biologiya, 22, 645-658, 1988), were introduced into VL611 using phage P1-mediated transduction giving the strain VL612.

At the third step, the mutation rhtA23 from the strain VKPM B-3996, conferring resistance to threonine and homoserine (US Patent No. 5,175,107) was introduced into VL612 by phage P1 transduction giving the strain VL613.

The *E. coli* strain VL614 was obtained by transduction of the wild-type allele of the *rhtA* gene from the *E. coli* strain VKPM B-6204 (MG1655 *zbi*3058::Tn10) to VL613. Transductants were selected on L-medium containing 10 mg/l tetracyclin, and among them the strain VL614 (rhtA⁺) sensitive to 10 g/l homoserine was found.

The strain VL614 was transformed with the pYGGA plasmid or with the pOK12 vector to obtain strains VL614/pYGGA (VKPM B-7719) and VL614/pOK12 (VKPM B-7722).

These strains were each cultivated at 37°C for 18 hours in a nutrient broth with 50 mg/l kanamycin, and 0.3 ml of the obtained culture was inoculated into 3 ml of a fermentation medium (Example 3) containing 0.3 g/l threonine, 0.3 g/l methionine and 50 mg/l kanamycin, in a 20 x 200 mm test tube, and cultivated at 37°C for 48 hours with a rotary shaker. After the cultivation, each accumulated amount of lysine and glutamate in the medium was determined by the known method.

The results are shown in Table 4.

Table 4

Strain	Lysine, g/l	Glutamate,
VL614/pOK12	2.6	0.8
VL614/pYGGA	3.6	2.2

As shown in Table 4, the strain VL614/pYGGA accumulated lysine in a larger amount than the strain VL614/pOK12 in which the yggA gene was not enhanced. Besides, the strain VL614/pYGGA accumulated more glutamic acid than the strain VL614/pOK12.

15

20

10

5

10

15

20

25

Example 5. Effect of yeaS, yahN, and yfiK DNA fragments amplification on threonine, alanine, valine and isoleucine production.

As the threonine-producing bacterium belonging to the genus *Escherichia*, the *E. coli* strain VL2054 was used. This strain was derived from the known *E. coli* strain VKPM B-3996 (US Patent No. 5,175,107) as follows.

Initially, a new recipient strain was constructed in several steps:

- The plasmidless derivative of the strain VKPM B-3996 was selected after spontaneous elimination of pVIC40 plasmid.
- '. The wild-type allele of the rhtA gene from the E. coli strain VKPM B-6204 (MG1655 zbi3058::Tn10) was introduced into the thus obtained strain by phage Pl mediated transduction as in the Example 4.
 - A mutation inactivating kan gene of the Tn5 transposon inserted into the tdh gene was obtained after NG mutagenesis and selection of kanamycin-sensitive cells still unable to degrade threonine. Thus the strain VL2053 was obtained.

On the other hand, the threonine operon from pVIC40 was cloned into integrative Mud vector under the P_R promoter of the phage lambda. In addition, the cat gene of Tn9 conferring the resistance to chloramphenical was cloned into the same vector. The construct thus obtained was inserted into the chromosome of the $E.\ coli$ strain C600 by use of the known method (US Patent No. 5,595,889) and transduced from

10

15

20

the thus obtained strain to VL2053, giving the new plasmidless threonine-producing strain VL2054. This strain accumulated in culture broth also alanine, valine and isoleucine.

The strain VL2054 was transformed with each of the plasmids pYEAS, pYFIK, and with the vector pUC21 to obtain E. coli strains VL2054/pYEAS (VKPM B-7707), VL2054/pYFIK (VKPM B-7712) and VL2054/pUC21 (VKPM B-7708).

These strains were each cultivated at 37°C for 18 hours in a nutrient broth with 100 mg/l ampicillin, and 0.3 ml of the obtained culture was inoculated into 3 ml of a fermentation medium (Example 3) containing 100 mg/l ampicillin, in a 20 x 200 mm test tube, and cultivated at 37°C for 48 hours with a rotary shaker. After the cultivation, each accumulated amount of threonine, alanine, valine and isoleucine in the medium was determined by known method.

The results are shown in Table 5.

As shown in Table 5, the strain VL2054/pYFIK accumulated threonine in a larger amount than the strain VL2054/pUC21 in which the yfiK gene was not enhanced. Besides, the strain VL2054/pYEAS accumulated more alanine, valine and isoleucine than the strain VL2054/pUC21 in which the yeaS gene was not enhanced.

Table 5

Strain	Amino acid accumulation, g/l			
	Threonine	Alanine	Valine	Isoleucine
VL2054/pUC21	5.8	0.4	0.31	0.15
VL2054/pYEAS	5.2	1.4	0.52	0.45
VL2054/pYFIK	8.8	0.5	0.22	0.14

Example 6. Effect of yeas and yfix DNA fragments amplification on histidine production.

As the histidine-producing bacterium belonging to the genus Escherichia, the strain E. coli VL2160 was used. This strain was obtained on the basis of the known strain NK5526 hisG::Tn10 (VKPM B-3384) by phage P1-mediated transduction $hisG^{R}$ the mutation desensitizing ATPphosphoribosyltransferase from the CC46 strain (Astvatsaturianz et al., Genetika, 24, 1928-1934, 1988). The strain E. coli VL2160 was transformed with each of the plasmids pYEAS, pYFIK, and with the vectors pUC21 to obtain E. coli strains VL2160/pYEAS (VKPM B-7753), E. coli VL2160/pYFIK (VKPM B-7754), E. coli VL2160/pUC21 (VKPM B-7752).

These strains were each cultivated at 37°C for 18 hours in a nutrient broth with 100 mg/l ampicillin, and 0.3 ml of the obtained culture was inoculated into 3 ml of the fermentation medium (Example 3) containing an increased amount of yeast extract (3 g/l) and 100 mg/l ampicillin, in a 20 x 200 mm test tube, and cultivated at 34°C for 68 hours with a rotary shaker.

20

5

10

15

After the cultivation, an accumulated amount of histidine in the medium was determined by known method. The results are shown in Table 6.

Table 6

Strain	Histidine, g/l
VL2160/pUC21	1.2
VL2160/pYEAS	1.8
VL2160/pYFIK	1.4

As shown in Table 6, the strains E. coli VL2160/pYFIX accumulated histidine in a larger amount than the strain E. coli VL2160/pUC21 in which the yeaS and yfiK genes were not enhanced.

Example 7. Effect of yahN, yfiK and yeaS DNA fragments amplification on proline production.

As the proline-producing bacterium belonging to the genus <code>Escherichia</code>, the strain VL2151 (W3350 <code>proB* $\Delta putAP$ </code> Tn10) was used. This strain was obtained by transduction into W3350 of $\Delta putAP$ mutation linked to Tn10 and selecting tetracycline-resistant transductants unable to utilize proline as a sole carbon source. The thus obtained strain W3350 $\Delta putAP$ Tn10 was mutagenized with NG and mutants resistant to 20 mg/l of 3,4-dehydro-DL-proline were selected. Among them the strain VL2151 (W3350 <code>proB* $\Delta putAP$ </code> Tn10) was found capable to produce proline.

10

15

20

5

10

15

20

The strain *E. coli* VL2151 was transformed with each of the plasmids pYEAS, pYFIK, pYAHN and with the vectors pUC21 to obtain *E. coli* strains VL2151/pYEAS (VKPM B-7714), VL2151/pYFIK (VKPM B-7713), VL2151/pYAHN (VKPM B-7748) and *E. coli* VL2151/pUC21 (VKPM B-7715).

These strains were each cultivated at 37°C for 18 hours in a nutrient broth with 100 mg/l ampicillin, and 0.3 ml of the obtained culture was inoculated into 3 ml of a fermentation medium (Example 3) containing 100 mg/l ampicillin, in a 20 x 200 mm test tube, and cultivated at 37°C for 48 hours with a rotary shaker. After the cultivation, an accumulated amount of proline in the medium was determined by known method. The results are shown in Table 7.

.

Table 7

Strain	Proline, g/l
VL2151/pUC21	1.8
VL2151/pYAHN	2.2
VL2151/pYEAS	2.1
VL2151/pYFIK	2.5

As shown in Table 7, the strains $E.\ coli$ VL2151/pYFIK, $E.\ coli$ VL2151/pYAHN and $E.\ coli$ VL2151/pYEAS accumulated proline in a larger amount than the strain $E.\ coli$ VL2151/pUC21 in which the yfiK, yahN and yeaS genes were not enhanced. The amplification of yfiK gene had the most pronounced effect.

10

15

20

Example 8. Effect of yggA DNA fragments amplification on arqinine production.

As arginine-producing bacterium belonging to the genus Escherichia, the strain W3350 argE::Tn10/pKA10 was used. This strain harbors a plasmid, pKA10, containing DNA region from Corynebacterium (Brevibacterium) flavum which complements at least argA and argE mutations in the recipient strain of E. coli K-12 (Kharitonov A. and Tarasov A.P. Molecular Genetics, Microbiology and Virology. No.9, 29-33, 1986).

The strain *E. coli* W3350 argE::Tn10/pKA10 was transformed with the plasmid pYGGA, or with the vector pOK12 to obtain the strains *E. coli* W3350 argE::Tn10/pKA10, pYGGA (VKPM B-7716) and *E. coli* W3350 argE::Tn10/pKA10, pOK12 (VKPM B-7718).

The thus obtained transformants were each cultivated at 37°C for 18 hours in a nutrient broth with 100 mg/l ampicillin and 50 mg/l kanamycin, and 0.3 ml of the obtained culture was inoculated into 3 ml of a fermentation medium (Example 3) containing 100 mg/l ampicillin and 50 mg/l kanamycin, in a 20 x 200 mm test tube, and cultivated at 37°C for 48 hours with a rotary shaker. After the cultivation, an accumulated amount of arginine in the medium was determined by known method.

25 The results are shown in Table 8.

Table 8

Strain	Arginine, g/l
W3350 argE::Tn10/pKA10, pOK12	0.11
W3350 argE::Tn10/pKA10, pYGGA	0.46

As shown in Table 8, the strains *E. coli* W3350 argE::Tn10/pKA10, pYGGA accumulated arginine in a larger amount than the strain *E. coli* W3350 argE::Tn10/pKA10, pUC21 in which the yggA qene was not enhanced.

The following *E. coli* strains have been deposited (according to international deposition based on Budapest Treaty) in the Russian National Collection of Industrial Microorganisms (VKPM) on December 29, 1998 under the accession numbers shown in parenthesis.

AJ13199/pUC21 (VKPM B-7728)

AJ13199/pYAHN (VKPM B-7729)

AJ13199/pYEAS (VKPM B-7731)

AJ13199/pYFIK (VKPM B-7730)

VL614/pYGGA (VKPM B-7719)

VL614/pOK12 (VKPM B-7722)

VL2054/pYEAS (VKPM B-7707)

VL2054/pYFIK (VKPM B-7712)

VL2054/pUC21 (VKPM B-7708)

VL2160/pYEAS (VKPM B-7753)

VL2160/pYFIK (VKPM B-7754)

VL2160/pUC21 (VKPM B-7752)

15

20

5

10

```
VL2151/pYFIK (VKPM B-7713)
```

VL2151/pYEAS (VKPM B-7714)

VL2151/pYAHN (VKPM B-7748)

VL2151/pUC21 (VKPM B-7715)

W3350 argE::Tn10/pKA10, pYGGA (VKPM B-7716)

W3350 argE::Tn10/pKA10, pOK12 (VKPM B-7718)

SEQUENCE LISTING

<110> Ajinomoto Co., Inc. <120> Method for Producing L-Amino Acid <130> <160> 24 <210> 1 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: primer for amplifying Escherichia coli vahN gene <400> 1 ggcgagctcc cagtaaccgg aaataag 27 <210> 2 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: primer for amplifying Escherichia coli yahN gene <400> 2 cgctctagaa aggaccacgc attacgg 27

<210> 3

<211> 27

· <212> DNA

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yeaS gene
<400> 3
ggcgagctca gattggttag catattc
                                                                    27
<210> 4
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yeaS gene
<400> 4
cggtctagaa tcagcgaaga atcaggg
                                                                    27
<210> 5
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yfiK gene
<400> 5
ggcgagctca tgttccgtgt cgggtac
                                                                    27
<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yfiK gene
```

```
<400> 6
ggctctagat agcaagttac taagcgg
                                                                   27
<210> 7
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yagA gene
<400> 7
ctctgaattc tctcttatta gtttttctga ttgcc
                                                                   35
<210> 8
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yggA gene
<400> 8
cgtgacctgc agcgttctca cagcgcggta gcctttaa
                                                                   38
<210> 9
<211> 672
<212> DNA
<213> Escherichia coli
<220>
<221> CDS
<222> (1)..(672)
<400> 9
atg atg cag tta gtt cac tta ttt atg gat gaa atc act atg gat cct
Met Met Gln Leu Val His Leu Phe Met Asp Glu Ile Thr Met Asp Pro
                  5
                                     10
ttg cat gcc gtt tac ctg acc gta gga ctg ttc gtg att act ttt ttt
Leu His Ala Val Tyr Leu Thr Val Gly Leu Phe Val Ile Thr Phe Phe
```

			20				25			30		
	ccg Pro											144
	cga Arg 50											192
	ttt Phe											240
	tgt Cys											288
	tta Leu											336
-	agc Ser					-						384
	cgc Arg 130											432
	atc Ile					gta			gaa			480
gca	cgt Arg											528
-	gtt Val			-								576
	999 Gly						agt			Ala		624
	gta Val 210	Phe									tga	672
<21 <21	0> 1 1> 2 2> P 3> E	23 RT	rich	ia c	oli							

```
<400> 10
Met Met Gln Leu Val His Leu Phe Met Asp Glu Ile Thr Met Asp Pro
                  5
                                     10
Leu His Ala Val Tyr Leu Thr Val Gly Leu Phe Val Ile Thr Phe Phe
                                  25
Asn Pro Gly Ala Asn Leu Phe Val Val Val Gln Thr Ser Leu Ala Ser
                             40
                                                  45
Gly Arg Arg Ala Gly Val Leu Thr Gly Leu Gly Val Ala Leu Gly Asp
                         55
                                              60
Ala Phe Tyr Ser Gly Leu Gly Leu Phe Gly Leu Ala Thr Leu Ile Thr
                     70
Gln Cys Glu Glu Ile Phe Ser Leu Ile Arg Ile Val Gly Gly Ala Tyr
                 85
                                     90
Leu Leu Trp Phe Ala Trp Cys Ser Met Arg Arg Gln Ser Thr Pro Gln
                                 105
Met Ser Thr Leu Gln Gln Pro Ile Ser Ala Pro Trp Tyr Val Phe Phe
        115
                            120
Arg Arg Gly Leu Ile Thr Asp Leu Ser Asn Pro Gln Thr Val Leu Phe
                        135
Phe Ile Ser Ile Phe Ser Val Thr Leu Asn Ala Glu Thr Pro Thr Trp
                    150
                                         155
Ala Arg Leu Met Ala Trp Ala Gly Ile Val Leu Ala Ser Ile Ile Trp
                165
                                     170
                                                         175
Arg Val Phe Leu Ser Gln Ala Phe Ser Leu Pro Ala Val Arg Arg Ala
            180
                                 185
Tyr Gly Arg Met Gln Arg Val Ala Ser Arg Val Ile Gly Ala Ile Ile
                            200
Gly Val Phe Ala Leu Arg Leu Ile Tyr Glu Gly Val Thr Gln Arg
    210
                        215
<210> 11
<211> 639
<212> DNA
<213> Escherichia coli
<220>
<221> CDS
<222> (1)..(639)
<400> 11
gtg ttc gct gaa tac ggg gtt ctg aat tac tgg acc tat ctg gtt ggg
```

Met 1	Phe	Ala	Glu	Tyr 5	G1 y	Val	Leu	Asn	Tyr 10	Trp	Thr	Tyr	Leu	Val 15	Gly	
	att Ile															96
	aat Asn															144
	gta Val 50															192
	gcg Ala															240
	ctt Leu															288
	acc Thr															336
	ggt Gly															384
	gcc Ala 130															432
	gcc Ala															480
	ctg Leu															528
	gtc Val															576
	tca Ser															624
	ctg Leu 210			tga												639

<220> <221> CDS

```
<210> 12
<211> 212
<212> PRT
<213> Escherichia coli
<400> 12
Met Phe Ala Glu Tyr Gly Val Leu Asn Tyr Trp Thr Tyr Leu Val Gly
  1
                                      10
Ala Ile Phe Ile Val Leu Val Pro Gly Pro Asn Thr Leu Phe Val Leu
Lys Asn Ser Val Ser Ser Gly Met Lys Gly Gly Tyr Leu Ala Ala Cys
                             40
Gly Val Phe Ile Gly Asp Ala Val Leu Met Phe Leu Ala Trp Ala Gly
Val Ala Thr Leu Ile Lys Thr Thr Pro Ile Leu Phe Asn Ile Val Arg
                     70
Tyr Leu Gly Ala Phe Tyr Leu Leu Tyr Leu Gly Ser Lys Ile Leu Tyr
                 85
Ala Thr Leu Lys Gly Lys Asn Ser Glu Ala Lys Ser Asp Glu Pro Gln
            100
                                105
Tyr Gly Ala Ile Phe Lys Arg Ala Leu Ile Leu Ser Leu Thr Asn Pro
                            120
Lys Ala Ile Leu Phe Tyr Val Ser Phe Phe Val Gln Phe Ile Asp Val
    130
                        135
                                             140
Asn Ala Pro His Thr Gly Ile Ser Phe Phe Ile Leu Ala Ala Thr Leu
                    150
                                        155
Glu Leu Val Ser Phe Cys Tyr Leu Ser Phe Leu Ile Ile Ser Gly Ala
                165
                                    170
Phe Val Thr Gln Tyr Ile Arg Thr Lys Lys Leu Ala Lys Val Gly
                                185
Asn Ser Leu Ile Gly Leu Met Phe Val Gly Phe Ala Ala Arg Leu Ala
        195
                            200
                                                205
Thr Leu Gln Ser
    210
<210> 13
<211> 588
<212> DNA
<213> Escherichia coli
```

<222> (1)..(588)

<400)> 13	}														
gtg	aca	ccg	acc	ctt	tta	agt	gct	ttt	tgg	act	tac	acc	ctg	att	acc	48
Met	Thr	Pro	Thr		Leu	Ser	Ala	Phe		Thr	Tyr	Thr	Leu		Thr	
1				5					10					15		
						aac										96
Ala	Met	Thr		Gly	Pro	Asn	Asn		Leu	Ala	Leu	Ser		Ala	Thr	
			20					25					30			444
						agt Ser										144
361	1113	35	1116	ni y	um	361	40	AI 9	vai	Leu	міа	45	ne c	Sei	Leu	
qqa	ttt		att	ata	atq	tta		tat	aca	aac	att		ttt	tca	cta	192
						Leu										
	50					55					60					
						gcg										240
	Val	Ile	Asp	Pro		Ala	Val	His	Leu		Ser	Trp	Ala	Gly		
65					70					75					80	
						gcg										288
АТА	ıуг	11e	vai	1rp 85	Leu	Ala	ırp	Lys	90	АІа	Inr	5er	Pro	95	Lys	
gaa	gac	aga	ctt		aca	aaa	cca	atc		+++	ton	acc	anc		act	336
						Lys										000
			100			-,-		105					110			
						aaa										384
Leu	Gln		Val	Asn	Val	Lys		Ile	Leu	Tyr	Gly	Val	Thr	Ala	Leu	
		115					120					125				
						caa										432
5er	130	rne	vai	Leu	Pro	G1n 135	Ihr	GIN	Ala	Leu	Ser 140	Irp	Val	Val	Gly	
atc		att	tta	cta	aca	atg	att	aaa	200	+++		22+	ata	tac	taa	480
						Met										400
145					150			,		155	٠.,	,,,,,,,	٠	0,0	160	
gcg	ctg	gcg	999	cat	ctg	ttt	cag	cga	ttg	ttt	cgc	cag	tat	ggt		528
Ala	Leu	Ala	G1y	His	Leu	Phe	G1n	Arg	Leu	Phe	Arg	G1n	Tyr	Gly	Arg	
				165					170					175		
						gcc										576
Gln	Leu	Asn		۷a1	Leu	Ala	Leu		Leu	Val	Tyr	Cys		Val	Arg	
-44	ш.	1.1	180					185					190			500
	ttc		taa													588
116	Phe	195														
		, ,,,														

<222> (1)..(636)

```
<210> 14
<211> 195
<212> PRT
<213> Escherichia coli
<400> 14
Met Thr Pro Thr Leu Leu Ser Ala Phe Trp Thr Tyr Thr Leu Ile Thr
                                     10
Ala Met Thr Pro Gly Pro Asn Asn Ile Leu Ala Leu Ser Ser Ala Thr
                                  25
Ser His Gly Phe Arg Gln Ser Thr Arg Val Leu Ala Gly Met Ser Leu
Gly Phe Leu Ile Val Met Leu Leu Cys Ala Gly Ile Ser Phe Ser Leu
Ala Val Ile Asp Pro Ala Ala Val His Leu Leu Ser Trp Ala Gly Ala
                     70
                                          75
Ala Tyr Ile Val Trp Leu Ala Trp Lys Ile Ala Thr Ser Pro Thr Lys
                 85
                                      90
Glu Asp Gly Leu Gln Ala Lys Pro Ile Ser Phe Trp Ala Ser Phe Ala
            100
                                 105
Leu Gln Phe Val Asn Val Lys Ile Ile Leu Tyr Gly Val Thr Ala Leu
                            120
Ser Thr Phe Val Leu Pro Gln Thr Gln Ala Leu Ser Trp Val Val Gly
                        135
                                            140
Val Ser Val Leu Leu Ala Met Ile Gly Thr Phe Gly Asn Val Cys Trp
                    150
                                         155
Ala Leu Ala Gly His Leu Phe Gln Arg Leu Phe Arg Gln Tyr Gly Arg
                165
                                     170
Gln Leu Asn Ile Val Leu Ala Leu Leu Leu Val Tyr Cys Ala Val Arg
            180
                                 185
                                                     190
Ile Phe Tyr
        195
<210> 15
<211> 636
<212> DNA
<213> Escherichia coli
<220>
<221> CDS
```

)> 1															
gtg	ttt	tct	tat	tac	ttt	caa	ggt	ctt	gca	ctt	999	gcg	gct	atg	atc	48
	Phe	Ser	Tyr		Phe	Gln	Gly	Leu	Ala	Leu	Gly	Ala	Ala	Met	Ile	
. 1				5					10					15		
cta	ccg	ctc	ggt	cca	caa	aat	gct	ttt	gtg	atg	aat	cag	ggc	ata	cgt	96
Leu	Pro	Leu		Pro	Gln	Asn	Ala		Val	Met	Asn	Gln	Gly	Ile	Arg	
			20					25					30			
cgt	cag	tac	cac	att	atg	att	gcc	tta	ctt	tgt	gct	atc	agc	gat	ttg	144
Arg	uin		HIS	11e	Met	He		Leu	Leu	Cys	Ala	Ile	Ser	Asp	Leu	
4	_4_	35	4				40					45				
y.I	ctg	att	tgc	gcc	999	att	TTT	ggt	ggc	agc	gcg	tta	ttg	atg	cag	192
vai	50	rie	cys	АГА	GIY	55	rne	GIY	ыу	5er		Leu	Leu	Met	Gin	
ton		+00	++-	ota	a0a		a+ a		+		60	gta				040
Ser	Pro	Trn	Leu	Lou	M1a	Lou	Val	The	Tro	ggc	ggc	gta Val	gcc	TTC	ttg	240
65	110	пр	Leu	Leu	70	Leu	vai	1111	пþ	75	ч	vai	Ala	rne	80	
	t.aa	tat	aat	t ++		act	+++	222	202		ata	agc	aat	22+		288
Leu	Trp	Tvr	Glv	Phe	Glv	Ala	Phe	lvs	Thr	Ala	Met	Ser	Ser	Acn	Ila	200
		.,.	,	85	,			_,0	90	,,,,a	1100	001	001	95	116	
gag	tta	gcc	agc	gcc	gaa	gtc	atq	aaq		ggc	aga	tgg	aaa		atc	336
Glu	Leu	Ala	Ser	Ala	G1u	Val	Met	Lys	G1n	G1y	Arg	Trp	Lvs	Ile	Ile	
			100					105			•	•	110			
gcc	acc	atg	ttg	gca	gtg	acc	tgg	ctg	aat	ccg	cat	gtt	tac	ctg	gat	384
Ala	Thr	Met	Leu	Ala	Val	Thr	Trp	Leu	Asn	Pro	His	Val	Tyr	Leu	Asp	
		115					120					125				
act	ttt	gtt	gta	ctg	ggc	agc	ctt	ggc	999	caa	ctt	gat	gtg	gaa	cca	432
Thr		Val	Val	Leu	Gly		Leu	Gly	Gly	Gln		Asp	Val	Glu	Pro	
	130					135					140					
aaa	cgc	tgg	ttt	gca	ctc	999	aca	att	agc	gcc	tct	ttc	ctg	tgg	ttc	480
	Arg	ırp	rne	Ala		Gly	Ihr	He	Ser		Ser	Phe	Leu	Trp		
145	+	-+-			150					155					160	
Dho	GIV	Lou	41.	CLL	CLC	gca	gcc	tgg	ctg	gca	ccg	cgt	ctg	cgc	acg	528
rne	uly	Leu	на	165	Leu	Ala	Ala	ГГÞ	170	АТА	Pro	Arg	Leu		Ihr	
ac a	222	003	can		2++	2+0	+	a+ a		a+ =				175	4	F70
Δla	lve	ηCα	Gla	Ara	Ila	Ila	Aco	Lau	gtt V-1	gtg	gga	tgt Cys	gtt	atg	tgg	576
πια	Lys	nia	180	AI 9	116	116	ASII	185	vai	vai	uly	cys	190	Met	ırp	
+++	att	acc		can	cta	aca	202		aa+	2++	act	cat				604
Phe	Ile	Ala	Leu	Gln	Len	Ala	Arc	Asn	99 L	Ile	Δla	His	yca Ma	Caa	ycc Ala	624
		195		2			200	.,	J 1 9	110	,,,,	205	rid	GIII	піа	
ttg	ttc		tag									200				636
_		-	-													000

```
Leu Phe Ser
    210
<210> 16
<211> 211
<212> PRT
<213> Escherichia coli
<400> 16
Met Phe Ser Tyr Tyr Phe Gln Gly Leu Ala Leu Gly Ala Ala Met Ile
 1
                                     10
Leu Pro Leu Gly Pro Gln Asn Ala Phe Val Met Asn Gln Gly Ile Arg
Arg Gln Tyr His Ile Met Ile Ala Leu Leu Cys Ala Ile Ser Asp Leu
         35
                             40
Val Leu Ile Cys Ala Gly Ile Phe Gly Gly Ser Ala Leu Leu Met Gln
                         55
Ser Pro Trp Leu Leu Ala Leu Val Thr Trp Gly Gly Val Ala Phe Leu
                     70
                                          75
Leu Trp Tyr Gly Phe Gly Ala Phe Lys Thr Ala Met Ser Ser Asn Ile
                 85
Glu Leu Ala Ser Ala Glu Val Met Lys Gln Gly Arg Trp Lys Ile Ile
            100
                                105
Ala Thr Met Leu Ala Val Thr Trp Leu Asn Pro His Val Tyr Leu Asp
                            120
Thr Phe Val Val Leu Gly Ser Leu Gly Gly Gln Leu Asp Val Glu Pro
                        135
                                            140
Lys Arg Trp Phe Ala Leu Gly Thr Ile Ser Ala Ser Phe Leu Trp Phe
                    150
                                        155
Phe Gly Leu Ala Leu Leu Ala Ala Trp Leu Ala Pro Arg Leu Arg Thr
                165
                                    170
Ala Lys Ala Gln Arg Ile Ile Asn Leu Val Val Gly Cys Val Met Trp
                                185
Phe Ile Ala Leu Gln Leu Ala Arg Asp Gly Ile Ala His Ala Gln Ala
        195
                            200
                                                 205
Leu Phe Ser
    210
<210> 17
```

<211> 20

<212> DNA

<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yahN gene
<400> 17
gtgtggaacc gacgccggat
                                                                      20
<210> 18
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yahN gene
<400> 18
tgttgtatgg tacggggttc gag
                                                                      23
<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yeaS gene
<400> 19
ctttgccaat cccgtctccc
                                                                      20
<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for amplifying Escherichia
coli yeaS gene
<400> 20
```

gccccatgca taacggaaag	20
<210> 21	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
210. All official dequation	
<220>	
<223> Description of Artificial Sequence: primer for amplifying Esche	richia
coli yfiK gene	
<400> 21	
	00
gaagatettg taggeeggat aaggeg	26
<210> 22	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: primer for amplifying Esche	richia
coli yfiK gene	
<400> 22	
tggttttacc aattggccgc	20
<210> 23	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: primer for amplifying Esche	richia
coli yggA gene	
<400> 23	
acttctcccg cgagccagtt c	01
according ogagoougue o	21
<210> 24	
<211> 21	
<212> DNA	
<213> Artificial Sequence	

<220>

<223> Description of Artificial Sequence: primer for amplifying Escherichia

<400> 24

ggcaagctta gcgcctctgt t

21

What is claimed is:

5

10

15

20

30

- 1. A bacterium belonging to the genus Escherichia and having an ability to produce an L-amino acid, wherein the ability to produce the L-amino acid is increased by increasing an expression amount of at least one protein selected from the group consisting of the following proteins of (A) to (H):
- (A) a protein having an amino acid sequence shown in SEQ ID NO: 10 in Sequence Listing;
- (B) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 10 in Sequence Listing, and which has an activity of increasing the ability to produce the L-amino acid of the bacterium having the protein;
- (C) a protein having an amino acid sequence shown in SEQ ID NO: 12 in Sequence Listing;
- (D) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 12 in Sequence Listing, and which has an activity of increasing the ability to produce the L-amino acid of the bacterium having the protein;
- (E) a protein having an amino acid sequence shown in 25 SEQ ID NO: 14 in Sequence Listing;
 - (F) a protein which has an amino acid sequence including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 14 in Sequence Listing, and which has an activity of increasing the ability to produce the

20

25

L-amino acid of the bacterium having the protein;

- (G) a protein having an amino acid sequence shown in SEQ ID NO: 16 in Sequence Listing; or
- (H) a protein which has an amino acid sequence.
 5 including deletion, substitution, insertion, addition or inversion of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 16 in Sequence Listing, and which has an activity of increasing the ability to produce the
- 10 2. The bacterium according to claim 1, wherein said L-amino acid is L-lysine and an expression amount of at least one protein selected from the group consisting of said proteins (A) to (D), (G) and (H) is increased.

L-amino acid of the bacterium having the protein.

- 3. The bacterium according to claim 1, wherein said L-amino acid is L-glutamic acid and an expression amount of at least one protein selected from the group consisting of said proteins (A) to (H) is increased.
- 4. The bacterium according to claim 1, wherein said L-amino acid is L-alanine and an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.
 - 5. The bacterium according to claim 1, wherein said L-amino acid is L-valine and an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.
- 6. The bacterium according to claim 1, wherein said L-amino acid is L-histidine and an expression amount of at least one protein selected from the group consisting of said proteins (C) to (F) is increased.
- 30 7. The bacterium according to claim 1, wherein said L-

10

15

20

amino acid is L-proline and an expression amount of at least one protein selected from the group consisting of said proteins (A) to (F) is increased.

- 8. The bacterium according to claim 1, wherein said L-amino acid is L-threonine and an expression amount of at least one protein selected from the group consisting of said proteins (E) and (F) is increased.
 - 9. The bacterium according to claim 1, wherein said L-amino acid is L-arginine and an expression amount of at least one protein selected from the group consisting of said
- proteins (G) and (H) is increased.
 - 10. The bacterium according to claim 1, wherein said L-amino acid is L-isoleucine and an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.
 - 11. The bacterium according to any one of claims 1 to 10, wherein a copy number of a DNA coding for said protein in a cell is increased.
 - 12. The bacterium according to claim 11, wherein said DNA is carried on a multicopy vector in the cell.
 - 13. The bacterium according to claim 11, wherein said DNA is carried on a transposon in the cell.
 - 14. A method for producing an L-amino acid, comprising the steps of:
- 25 cultivating the bacterium as defined in claim 1 in a culture medium, to produce and accumulate the L-amino acid in the medium, and

recovering the L-amino acid from the medium.

15. The method according to claim 14, wherein said L-amino acid is L-lysine and said bacterium is one in which an

15

20

30

expression amount of at least one protein selected from the group consisting of said proteins (A) to (D), (G) and (H) is increased.

- 16. The method according to claim 14, wherein said L-amino acid is L-glutamic acid and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (A) to (H) is increased.
- 17. The method according to claim 14, wherein said L-amino acid is L-alanine and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.
 - 18. The method according to claim 14, wherein said L-amino acid is L-valine and said bacterium is one in which an expression amount of at least one protein selected from the
- group consisting of said proteins (C) and (D) is increased.

 19. The method according to claim 14, wherein said L-amino
 - acid is L-histidine and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (C) to (F) is increased.
- 20. The method according to claim 14, wherein said L-amino acid is L-proline and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (A) to (F) is increased.
- 25 21. The method according to claim 14, wherein said L-amino acid is L-threonine and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (E) and (F) is increased.
 - 22. The method according to claim 14, wherein said L-amino acid is L-arginine and said bacterium is one in which an

expression amount of at least one protein selected from the group consisting of said proteins (G) and (H) is increased.

- 23. The method according to claim 14, wherein said L-amino acid is L-isoleucine and said bacterium is one in which an expression amount of at least one protein selected from the group consisting of said proteins (C) and (D) is increased.
- 24. The method according to any one of claims 14 to 23, wherein a copy number of a DNA coding for said protein in a cell of said bacterium is increased.
- 25. The method according to claim 24, wherein said DNA is carried on a multicopy vector in the cell.
 - 26. The method according to claim 24, wherein said DNA is carried on a transposon in the cell.

Abstract of the Disclosure

A bacterium belonging to the genus Escherichia and having an ability to produce an L-amino acid, wherein the ability to produce the L-amino acid is increased by increasing an expression amount of an L-amino acid excretion protein, and a method for producing the L-amino acid using the bacterium.

Beclaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name.

We (I) believe that we are (I am) the original, first, and joint (sole) invertor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD F	OR PRODUCING L-AMINO ACID		
the specification	of which		
8	is attached hereto.		
	was filed on	a	s
	Application Serial No.		_
	and amended on	···	- •
	was filed as PCT international application		
7	Tumber		_
0	n		- >
a	nd was amended under PCT Article 19		
0	n	(if applicable)	

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Prior Clain		
98124016	Russia	30/12/1998	☑ Yes	□ No	
99104431	Russia	09/03/1999	☑ Yes	□ No	
			☐ Yes	□N∘	
<u>, , , , , , , , , , , , , , , , , , , </u>	3		☐ Yes	□ No	

We (I) hereby claim the benefit under	Title 35, United	States Code, §	119(e) of any	United States	provisional
application(s) listed below.					

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

We (1) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	abandoned)

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; and Richard L. Chinn, Registration Number 34,305; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Vitaliy Arkadievich LIVSHITS	Residence: Moscow Russia
NAME OF FIRST SOLE INVENTOR	
	Citizen: Russia
Cupsis	
Signature of Inventor	Post Office Address:kv. 84, korpus 1 Sumskoy proezd 5, Moscow, 113208,

November 24, 1999

Date

November 24, 1999

Residence: Moscow Russia
Citizen: Russia
Post Office Address: kv. 27, korpus 8, ulits Novatorov 40, Moscow, 117421, Russia
Residence: Yokohama-shi, Kanagawa, Japan
Citizen: Japanese
Post Office Address: Kuden-Haitsu 1-126, Kuden-Cho 873-5, Sakae-ku, Yokohama-shi 247-0014 Japan,
_
Redsidence: Moscow Russia
Citizen of: Russia
Citizen of: Russia - Post Office Address: pos Institute 6, Kaluga region, Borovsk, 249010, Russia
— Post Office Address: pos Institute 6,
— Post Office Address: pos Institute 6,
— Post Office Address: pos Institute 6,
Post Office Address: pos Institute 6, Kaluga region, Borovsk, 249010, Russia

1/95

Irina Lyvovna TOKHMAKOVA	
NAME OF SIXTH JOINT INVENTOR	Residence: Moscow Russia
Turner	Citizen of: Russia
Signature of Inventor	Post Office Address: kv. 26, s/p Vysotka 1, Isrtrinskiy r-n, Moscow region, 143513, Russia
November 24, 1999	
	Residence:
NAME OF SEVENTH JOINT INVENTOR	
c:	Citizen of:
Signature of Inventor	Post Office Address:
Date	
WALES OF THE STATE	Residence:
NAME OF EIGHTH JOINT INVENTOR	
Signature of Inventor	Citizen of:
organitate of inventor	Post Office Address:
Date	
NAME OF ANYON YOUR AND AND	Residence:
NAME OF NINTH JOINT INVENTOR	
Signature of Inventor	Citizen of:
	Post Office Address:
Date	

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page.

Moscow 113545
!-st Dorozhny proezd 1 Russia
name and address
of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2054(pYEAS)

AUTHORITY: VKPM B- 7707

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of threonine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the (date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM)

Depositary GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Where Rule 6.4(d) applies, such date is the date of depositary authority was acquired

Signature (s) of person(s) having the

Authority or authorized official(s):
Date: Sineoky S.P.

Which the status of international

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation CNUCENETIKA

INTERNATIONAL FORM recept in the case of an original deposot issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the

DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2054 (pUC21)

VKPM B-7708 ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of threonine, alanine

a proposed taxonomic designation

(Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

(date of original deposot) and a request to convert

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this international Depositary Authority

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATION & L. DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM)

Depositary GNIlgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the power to represent the International

Anthority or authorized official(s): Singolar S.P.

Appendix 3 page 14 Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To

State Scientific Centre of Russian Federation GNIIGENETIKA

INTERNATIONAL FORM

identified at the bottom of this page

recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2054(pYFIK)

VKPM B- 7712

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

a scintific description

Producer of threonine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

The microorganism identified under I above was received by this International Depositary Authority

on the

(date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

IV. RECEIPT OF REQUEST FOR CONVERSION

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary

GNIIgenetika

Address: Russia 113545 Moscow 1 Dorozhny proezd 1

Date:

to represent the International Authority or authorized officials): Sineoky S.P.

Signature (s) of person(s) having the

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY

identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

LIDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2151 (pYFIK)

VKPM B- 7713

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of proline

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary Signature (s) of person(s) having the power to represent the International

(date of original deposit) and a request to convert

GNIlgenetika

Address: Russia 113545 Moscow

Authority or authorized officials:

Date: Sineoky S.P.

Appendix 3 page 14 Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

State Scientific Centre of Russian Federation GNIIGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-

AUTHORITY: VKPM B-7714

Escherichia coli VL2151 (pYEAS)

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of proline

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

The microorganism identified under I above was received by this International Depositary Authority

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

IV. RECEIPT OF REQUEST FOR CONVERSION

Name: Russian National Collection of Industrial Microorganisms (VKP) Depositary GNHgenetika

Signature (s) of person(s) having the to represent the International

(date of original deposit) and a request to convert

Address: Russia 113545 Mosco

Date:

Authority or authorized official(s): ineoky S.D.

I Dorozhny proezd 1

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

State Scientific Centre of Russian Federation GNIIGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR Escherichia coli VL2151 (pUC21)

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY: VKPM B- 7715

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of proline

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

οn

(date of original deposit) and a request to convert

the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Denositary GNIIgenetika

Address: Russia 113545 Moscow 1 Dorozhny proezd 1

Where Rule 6.4(d) applies, such date is the date on wh depositary authority was acquired

Signature (s) of person(s) having the to represent the International

or authorized official(s): Sincoky S.P.

ich the status of international

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

State Scientific Centre of Russian Federation GNUGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

VKPM B- 7716

Escherichia coli W3350 argE::Tn10 (pKA10)(pYGGA)

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

a scintific description

Producer of arginine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

(date of original deposit) and a request to convert

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM Depositary

Signature (s) of person(s) having the to represent the International power

GNIIgenetika

Authority or authorized official(s): Sincoky SA Date:

Address: Russia 113545 Moscow 1 Dorozhny proezd 1

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the

Accession number given by the

VKPM B- 7718

DEPOSITOR

INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli W 3350 argE::Tn10 (pKA10)(pOK12)

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of arginine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the

(date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM Depositary

GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the to represent the International

Authority or authorized official(s) Date:

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

VKPM B-7719

Moscow 113545
!-st Dorozhny proezd 1 Russia
name and address
of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL614 (pYGGA)

IL SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of lysine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM)

Depositary GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the power to represent the International

(date of original deposit) and a request to convert

Authority or authorized official(s)



Appendix 3
page 14
Budapest treaty on the international
recognition of the deposit of microorganisms
for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNHGENETIKA

of depositor

INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545 !-st Dorozhity proced 1 Russia name and address

LIDENTIFICATION OF THE MICROORGANISM

Identification reservore given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli V L4.14 (pOK12)

VKPM B- 7722

HISCIENTIFIC DUSCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganis, a identified under I above was accompanied by:

x a scintific description

Producer of lysine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on

(date of original deposit) and a request to convert

original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary

GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd !

Signature (s) of person(s) having the power to corresent the International

Authorized official(s):

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545
!-st Dorozhny proezd I Russia
name and address
of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the

DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:
VKPM B- 7728

Escherichia coli AJ13199(pUC21)

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of glutamic acid

a proposed taxonomic designation (Mark with a cross where applicable)

III RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under l above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the (date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITA

Name: Russian National Collection of Industrial Microorganisms (Vicinity Collection) (Propository Collection) (Propositor

Signature (s) of person(s) having the wer to represent the International Authority or authorized official(s):

Date: Sineoky SA

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNUGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd I Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli AJ13199(pYAHN)

VKPM B- 7729

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of glutamic acid

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above.

IJ.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the

(date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary GNIIgenetika

Signature (s) of person(s) having the to represent the International

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Authority or authorized official(s): Date:

depositary authority was acquired

Where Rule 6.4(d) applies, such date is the date on which the status of international

Appendix 3 page 14 Budapest treaty on the international

recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545 1-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR Accession number given by the INTERNATIONAL DEPOSITARY-

Escherichia coli AJ13199(pYFIK)

AUTHORITY: VKPM B- 7730

ILSCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of glutamic acid

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under 1 above was received by this International Depositary
Authority

on the (date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary

GNIlgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the ower to represent the International

Authority or authorized official(s):

Appendix 3

page 14

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

State Scientific Centre of Russian Federation GNUGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR Escherichia coli AJ13199(pYEAS)

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY: VKPM B- 7731

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

a scintific description

Producer of glutamic acid

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

(date of original deposit) and a request to convert

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

οn the

original deposot to a deposit under the Budapest Treaty was received by it on

(date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Denositary

GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the to represent the International

uthorized official(s): Sineoky S.P.

Appendix 3
page 14
Budapest treaty on the international
recognition of the deposit of microorganisms
for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545
!-st Dorozhny proezd 1 Russia
name and address
of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2151 (pYAHN)

VKPM B- 7748

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of proline

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM Depositary GNIIgenetika

Address: Russia 113545 Moscow 1 Dorozhny proezd 1 Signature (s) of person(s) having the ower to represent the international

(date of original deposit) and a request to convert

Authority or authorized official(s): Date: Sineoky S.P.

Appendix 3
page 14
treaty on the international

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the

DEPOSITOR

Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:
VKPM B-7752

Escherichia coli VL2160 (pUC21)

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of histidine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on

(date of original deposit) and a request to convert

the
original deposot to a deposit under the Budapest Treaty was received by it on
(date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM Depositary GNIIgenetika

Address: Russia 113545 Moscow 1 Dorozhny proezd 1 Signature (s) of person(s) having the wer to represent the International

Authority or authorized official(s):
Date: Sineoky

Appendix 3 page 14 Budapest treaty on the international

recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA

INTERNATIONAL FORM recept in the case of an original deposit issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Moscow 113545 !-st Dorozhny proezd 1 Russia name and address of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the

Accession number given by the

DEPOSITOR

INTERNATIONAL DEPOSITARY-AUTHORITY: VKPM B- 7753

Escherichia coli VL2160 (pYEAS)

II.SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of histidine

a proposed taxonomic designation (Mark with a cross where applicable)

III RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above.

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

Ωn the

(date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM)

Depositary GNIIgenetika

Address: Russia 113545 Moscow

1 Dorozhny proezd 1

Signature (s) of person(s) having the power to represent the International

Date:

Authority or authorized official(s)

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired

Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure

To State Scientific Centre of Russian Federation GNIIGENETIKA INTERNATIONAL FORM
recept in the case of an original deposit
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

Moscow 113545
!-st Dorozhny proezd I Russia
name and address
of depositor

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR Accession number given by the INTERNATIONAL DEPOSITARY-AUTHORITY:

Escherichia coli VL2160 (pYFIK)

VKPM B- 7754

The microorganism identified under I above was accompanied by:

x a scintific description

Producer of histidine

a proposed taxonomic designation (Mark with a cross where applicable)

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I above,

IL SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

which was received by it on 29.12.1998

(date of original deposit)

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority

on the (date of original deposit) and a request to convert

original deposot to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: Russian National Collection of Industrial Microorganisms (VKPM) Depositary GNIIgenetika

Address: Russia 113545 Moscow 1 Dorozhny proezd 1

1 Where Rule 6.4(d) applies, such da depositary authority was acquired Signature (s) of person(s) having the ower to represent the International

Authority or authorized official(s)

uch the status of international